Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 6,739 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CHANGE Study Clear all
Completed Phase 1Phase 2 Interventional Results available

Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction

NCT02474199
View directory record Official record
Conditions
Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)
Interventions
darTregs, Acetaminophen, Diphenhydramine, Immunosuppression (IS) Withdrawal, Study Mandated Procedures
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 28, 2026, 6:54 PM EDT
Recruiting Phase 2 Interventional

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

NCT04745949
View directory record Official record
Conditions
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Interventions
Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decreasing Physician Burnout With Professional Coaching

NCT05583435
View directory record Official record
Conditions
Burnout, Professional
Interventions
One-on-one professional coaching, Small-group professional coaching
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 28, 2026, 6:54 PM EDT
Terminated Phase 4 Interventional

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

NCT02117076
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
Gabapentin immediate release, Gabapentin enacarbil extended release
Drug
Lead sponsor
Theresa Zesiewicz, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Alcohol PBS and Thinking About the Past

NCT05208593
View directory record Official record
Conditions
Alcohol Drinking in College
Interventions
Negative Event + Counterfactual Task, Personalized Normative Feedback, Negative Event + Factual Thinking Task, Negative Event Only
Behavioral
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional

Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection

NCT04694638
View directory record Official record
Conditions
Prone Positioning, Covid19, Hypoxemic Respiratory Failure, ARDS, Non Invasive Ventilation, High Flow Nasal Cannulla
Interventions
Body position change
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Juice Study: Sensitivity of Skin Carotenoid Status to Detect Change in Intake

NCT03202043
View directory record Official record
Conditions
Overweight
Interventions
High dose vegetable juice, Medium dose vegetable juice, Low dose vegetable juice, Control bottled water
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional

ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment

NCT02610517
View directory record Official record
Conditions
HIV, Alcoholism
Interventions
Provider Training, Patient Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 28, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

NCT05441826
View directory record Official record
Conditions
Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
VB119
Drug
Lead sponsor
Tenet Medicines
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

NCT00028314
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Wasting Disease
Interventions
Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 28, 2026, 6:54 PM EDT
Recruiting No phase listed Observational

Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

NCT07060547
View directory record Official record
Conditions
Alcoholic Hepatitis, Alcohol-related Liver Disease
Interventions
HepQuant DuO Test
Device
Lead sponsor
HepQuant, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional Results available

Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG

NCT01432626
View directory record Official record
Conditions
Stress Induced Cardiomyopathy
Interventions
I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 28, 2026, 6:54 PM EDT
Recruiting Phase 1 Interventional

Beta-blocker Administration for Cardiomyocyte Division

NCT04713657
View directory record Official record
Conditions
Tetralogy of Fallot, Double Outlet Right Ventricle
Interventions
N-thymidine, Urine Collection, Echocardiogram, Cardiac MRI (CMR), Propranolol Hydrochloride, Placebo, Physical Exam, Specimen Collection
Other · Procedure · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Days to 100 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Phase 1 Interventional

Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer

NCT03535701
View directory record Official record
Conditions
Stage IV Breast Cancer AJCC v6 and v7
Interventions
Dietary Intervention, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Dietary Supplement · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 28, 2026, 6:54 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Interventions
LOXO-292
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional Results available

Increasing Activity Post-Kidney Transplant With SystemCHANGE

NCT03191630
View directory record Official record
Conditions
Kidney Transplant; Complications, Physical Activity, Cardiorenal; Change, Cardiovascular Diseases
Interventions
Fitbit (Control), SystemCHANGE and Fitbit (Intervention)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 28, 2026, 6:54 PM EDT
Recruiting Phase 2 Interventional

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

NCT07037836
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
Interventions
Inhaled Treprostinil (Tyvaso Nebulizer)
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PFA-100 Responsive to Effect of Energy Drinks on Platelet Function

NCT02997111
View directory record Official record
Conditions
Platelet Function, Thrombosis
Interventions
PFA-100
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 28, 2026, 6:54 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

NCT04317105
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Echocardiography Test, Ipilimumab, Nivolumab, X-Ray Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • Austin, Texas • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03197766
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

NCT02541565
View directory record Official record
Conditions
Composite Lymphoma, Grade 3b Follicular Lymphoma, Stage I Diffuse Large B-Cell Lymphoma, Stage I Follicular Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage II Follicular Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage III Follicular Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma, Stage IV Follicular Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pembrolizumab, Prednisone, Rituximab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

NOURISH: Nourishing Our Understanding of Role Modeling to Improve Support and Health

NCT00628030
View directory record Official record
Conditions
Pediatric Obesity
Interventions
NOURISH, Wellness Group
Behavioral · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
Interventions
RP6530
Drug
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Duarte, California • Orange, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 28, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

NCT01942356
View directory record Official record
Conditions
Acute Cholecystitis, Chronic Cholecystitis
Interventions
TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia, TIVA - Tachycardia, INH - Hypotension, INH - Hypertension, INH - Bradycardia, INH - Tachycardia
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 28, 2026, 6:54 PM EDT